 Thomas Parker
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Circulation | 20 | 2006 | 431 | 1.420 |
Why?
| | Neonatology | 3 | 2017 | 23 | 1.050 |
Why?
| | Clinical Competence | 4 | 2024 | 1020 | 0.900 |
Why?
| | Competency-Based Education | 1 | 2024 | 71 | 0.870 |
Why?
| | Nitric Oxide Synthase | 16 | 2006 | 237 | 0.800 |
Why?
| | Parental Leave | 1 | 2022 | 24 | 0.790 |
Why?
| | Internship and Residency | 3 | 2024 | 1058 | 0.740 |
Why?
| | Sheep | 36 | 2010 | 845 | 0.740 |
Why?
| | Education, Medical, Graduate | 3 | 2024 | 443 | 0.730 |
Why?
| | Faculty, Medical | 1 | 2024 | 269 | 0.730 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 279 | 0.720 |
Why?
| | Fetus | 19 | 2005 | 782 | 0.690 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 40 | 0.600 |
Why?
| | Nitric Oxide | 18 | 2010 | 896 | 0.590 |
Why?
| | Communication Barriers | 1 | 2018 | 98 | 0.560 |
Why?
| | Vasodilation | 15 | 2005 | 476 | 0.560 |
Why?
| | Estradiol | 4 | 2001 | 494 | 0.520 |
Why?
| | Lung | 19 | 2006 | 3940 | 0.450 |
Why?
| | Parents | 2 | 2022 | 1319 | 0.440 |
Why?
| | Ductus Arteriosus | 10 | 2005 | 73 | 0.420 |
Why?
| | Pulmonary Artery | 10 | 2005 | 1097 | 0.410 |
Why?
| | Hypertension, Pulmonary | 12 | 2005 | 1897 | 0.380 |
Why?
| | Vascular Resistance | 9 | 2006 | 371 | 0.370 |
Why?
| | Nitric Oxide Synthase Type III | 9 | 2010 | 203 | 0.360 |
Why?
| | Animals, Newborn | 8 | 2005 | 834 | 0.310 |
Why?
| | Amides | 2 | 2006 | 91 | 0.290 |
Why?
| | Hemodynamics | 18 | 2006 | 1094 | 0.270 |
Why?
| | Curriculum | 1 | 2013 | 928 | 0.260 |
Why?
| | Pediatrics | 1 | 2013 | 1074 | 0.240 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 42 | 0.240 |
Why?
| | Utah | 1 | 2024 | 64 | 0.230 |
Why?
| | Formative Feedback | 1 | 2024 | 26 | 0.230 |
Why?
| | Sulfones | 1 | 2005 | 108 | 0.220 |
Why?
| | Vasoconstriction | 2 | 2005 | 199 | 0.220 |
Why?
| | Fetal Growth Retardation | 5 | 2010 | 549 | 0.220 |
Why?
| | Endothelium, Vascular | 4 | 2006 | 902 | 0.210 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 443 | 0.210 |
Why?
| | Nitroarginine | 8 | 2006 | 57 | 0.190 |
Why?
| | Educational Measurement | 1 | 2024 | 264 | 0.190 |
Why?
| | Focus Groups | 1 | 2024 | 450 | 0.190 |
Why?
| | Colorado | 2 | 2024 | 4410 | 0.190 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 46 | 0.180 |
Why?
| | Oxygen | 7 | 2004 | 916 | 0.180 |
Why?
| | Pregnancy | 17 | 2010 | 6423 | 0.160 |
Why?
| | Infant, Newborn | 11 | 2018 | 5772 | 0.160 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 422 | 0.150 |
Why?
| | Animals | 37 | 2010 | 35409 | 0.150 |
Why?
| | Blood Vessels | 1 | 2000 | 187 | 0.150 |
Why?
| | Gestational Age | 9 | 2010 | 876 | 0.140 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5437 | 0.140 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 378 | 0.140 |
Why?
| | Placenta | 5 | 2010 | 716 | 0.140 |
Why?
| | Bronchodilator Agents | 3 | 2007 | 245 | 0.130 |
Why?
| | Enzyme Inhibitors | 6 | 2006 | 827 | 0.130 |
Why?
| | Delphi Technique | 1 | 2017 | 227 | 0.130 |
Why?
| | Epoprostenol | 1 | 1997 | 136 | 0.130 |
Why?
| | Language | 1 | 2018 | 283 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 228 | 0.120 |
Why?
| | Physician's Role | 1 | 2017 | 206 | 0.120 |
Why?
| | High-Frequency Ventilation | 3 | 2000 | 45 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2005 | 528 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 1 | 1997 | 111 | 0.120 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2007 | 137 | 0.120 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2005 | 444 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 573 | 0.120 |
Why?
| | Blotting, Western | 6 | 2007 | 1204 | 0.110 |
Why?
| | Administration, Inhalation | 9 | 2007 | 673 | 0.110 |
Why?
| | Antihypertensive Agents | 2 | 2000 | 485 | 0.110 |
Why?
| | Physician Executives | 1 | 2013 | 33 | 0.100 |
Why?
| | Humans | 18 | 2024 | 129847 | 0.100 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 63 | 0.100 |
Why?
| | Lymphokines | 2 | 2002 | 127 | 0.100 |
Why?
| | Pulmonary Gas Exchange | 5 | 2005 | 121 | 0.100 |
Why?
| | United States | 2 | 2022 | 13913 | 0.090 |
Why?
| | Endothelin-1 | 4 | 2000 | 180 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2002 | 373 | 0.090 |
Why?
| | Education | 1 | 2011 | 104 | 0.090 |
Why?
| | Disease Models, Animal | 9 | 2010 | 4077 | 0.090 |
Why?
| | Data Collection | 1 | 2013 | 653 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2010 | 2703 | 0.080 |
Why?
| | Female | 19 | 2018 | 68829 | 0.080 |
Why?
| | Endothelin Receptor Antagonists | 3 | 2000 | 62 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 170 | 0.080 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 1999 | 103 | 0.070 |
Why?
| | Hyaline Membrane Disease | 2 | 1998 | 20 | 0.070 |
Why?
| | Umbilical Arteries | 2 | 2006 | 53 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 434 | 0.070 |
Why?
| | Fluorocarbons | 2 | 1999 | 109 | 0.070 |
Why?
| | Prospective Studies | 1 | 2018 | 7158 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 133 | 0.070 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2006 | 28 | 0.060 |
Why?
| | Fetal Diseases | 2 | 2004 | 164 | 0.060 |
Why?
| | Ligation | 3 | 2002 | 87 | 0.060 |
Why?
| | Vasodilator Agents | 3 | 2003 | 326 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1106 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2006 | 87 | 0.060 |
Why?
| | Uterus | 2 | 2006 | 207 | 0.060 |
Why?
| | Positive-Pressure Respiration | 2 | 2003 | 78 | 0.060 |
Why?
| | Immunohistochemistry | 4 | 2006 | 1690 | 0.060 |
Why?
| | Regional Blood Flow | 3 | 2006 | 463 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 72 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2005 | 72 | 0.060 |
Why?
| | Endothelin B Receptor Antagonists | 1 | 2004 | 11 | 0.060 |
Why?
| | Cyclic GMP | 2 | 2001 | 90 | 0.060 |
Why?
| | Hypertension | 2 | 2005 | 1242 | 0.060 |
Why?
| | Drug Combinations | 1 | 2005 | 331 | 0.050 |
Why?
| | Receptors, Endothelin | 2 | 2000 | 50 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2006 | 2016 | 0.050 |
Why?
| | Isoenzymes | 2 | 2001 | 301 | 0.050 |
Why?
| | Vasomotor System | 2 | 2002 | 44 | 0.050 |
Why?
| | Embryonic and Fetal Development | 2 | 2000 | 95 | 0.050 |
Why?
| | Blotting, Northern | 2 | 2000 | 196 | 0.050 |
Why?
| | Child | 1 | 2022 | 20962 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2005 | 342 | 0.050 |
Why?
| | Hernia, Diaphragmatic | 1 | 2003 | 69 | 0.050 |
Why?
| | Piperidines | 2 | 2004 | 200 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 297 | 0.050 |
Why?
| | Oligopeptides | 2 | 2004 | 260 | 0.050 |
Why?
| | Pyridines | 1 | 2006 | 478 | 0.050 |
Why?
| | Respiration, Artificial | 4 | 2001 | 617 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 12467 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2007 | 300 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2004 | 403 | 0.050 |
Why?
| | Blood Gas Analysis | 2 | 2000 | 73 | 0.050 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 26 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 53 | 0.050 |
Why?
| | Prostaglandins | 1 | 2001 | 94 | 0.050 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 68 | 0.050 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2003 | 145 | 0.050 |
Why?
| | Recombinant Proteins | 4 | 2005 | 1311 | 0.050 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 78 | 0.040 |
Why?
| | Placental Insufficiency | 1 | 2002 | 112 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 151 | 0.040 |
Why?
| | Organ Specificity | 1 | 2001 | 295 | 0.040 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 176 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 59 | 0.040 |
Why?
| | Plethysmography | 1 | 2001 | 106 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 886 | 0.040 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2003 | 205 | 0.040 |
Why?
| | Endothelins | 1 | 2000 | 62 | 0.040 |
Why?
| | Physical Stimulation | 1 | 2000 | 75 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2001 | 766 | 0.040 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2000 | 145 | 0.040 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 63 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 36 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2000 | 160 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2010 | 820 | 0.040 |
Why?
| | Receptor, Endothelin B | 3 | 2004 | 50 | 0.040 |
Why?
| | Medical Records | 1 | 1998 | 171 | 0.030 |
Why?
| | Adult | 2 | 2018 | 35634 | 0.030 |
Why?
| | Male | 4 | 2018 | 63759 | 0.030 |
Why?
| | Biological Products | 1 | 2000 | 207 | 0.030 |
Why?
| | Signal Transduction | 2 | 2010 | 4935 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1997 | 106 | 0.030 |
Why?
| | Capillary Permeability | 1 | 1997 | 141 | 0.030 |
Why?
| | Blood Pressure | 4 | 2005 | 1736 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 1997 | 98 | 0.030 |
Why?
| | Pulsatile Flow | 2 | 2006 | 60 | 0.030 |
Why?
| | Acetylcholine | 3 | 2001 | 184 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1291 | 0.030 |
Why?
| | Neutrophils | 2 | 1999 | 1209 | 0.030 |
Why?
| | Echocardiography | 1 | 1997 | 636 | 0.030 |
Why?
| | Stress, Mechanical | 3 | 2001 | 467 | 0.030 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 78 | 0.030 |
Why?
| | Pilot Projects | 1 | 1998 | 1597 | 0.030 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 78 | 0.030 |
Why?
| | Inflammation | 1 | 2003 | 2748 | 0.020 |
Why?
| | Hypoxia | 1 | 1998 | 1087 | 0.020 |
Why?
| | Liability, Legal | 1 | 2011 | 41 | 0.020 |
Why?
| | Medical Staff, Hospital | 1 | 2011 | 81 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2001 | 171 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2010 | 83 | 0.020 |
Why?
| | Reference Values | 2 | 2002 | 796 | 0.020 |
Why?
| | Uterine Artery | 1 | 2010 | 78 | 0.020 |
Why?
| | Hyperthermia, Induced | 1 | 2010 | 108 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 39 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 46 | 0.020 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.020 |
Why?
| | Carbon Dioxide | 2 | 2000 | 260 | 0.020 |
Why?
| | Fetal Weight | 1 | 2007 | 55 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 339 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 284 | 0.020 |
Why?
| | Peptides, Cyclic | 2 | 1998 | 256 | 0.020 |
Why?
| | Lung Compliance | 1 | 2005 | 48 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 954 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2003 | 14553 | 0.010 |
Why?
| | Radiography | 1 | 2007 | 800 | 0.010 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2005 | 66 | 0.010 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2005 | 33 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 778 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 631 | 0.010 |
Why?
| | Treatment Outcome | 1 | 1998 | 10241 | 0.010 |
Why?
| | Parturition | 1 | 2004 | 71 | 0.010 |
Why?
| | Chronic Disease | 2 | 2002 | 1724 | 0.010 |
Why?
| | Trachea | 1 | 2005 | 231 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 836 | 0.010 |
Why?
| | Ventilator Weaning | 1 | 2003 | 36 | 0.010 |
Why?
| | Chromones | 1 | 2002 | 45 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 406 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 107 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 55 | 0.010 |
Why?
| | Placentation | 1 | 2002 | 43 | 0.010 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2002 | 24 | 0.010 |
Why?
| | Morpholines | 1 | 2002 | 123 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 29 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 10 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.010 |
Why?
| | Time Factors | 2 | 2003 | 6550 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 146 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 145 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2001 | 80 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 16 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 41 | 0.010 |
Why?
| | Guanidines | 1 | 2001 | 37 | 0.010 |
Why?
| | Morphogenesis | 1 | 2002 | 158 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 161 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 813 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 164 | 0.010 |
Why?
| | Pressure | 1 | 2002 | 240 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2002 | 176 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 362 | 0.010 |
Why?
| | Calibration | 1 | 2001 | 140 | 0.010 |
Why?
| | Body Weight | 1 | 2004 | 947 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2724 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 397 | 0.010 |
Why?
| | Respiration | 1 | 2001 | 193 | 0.010 |
Why?
| | Trophoblasts | 1 | 2002 | 189 | 0.010 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2000 | 28 | 0.010 |
Why?
| | Pulmonary Surfactants | 1 | 2000 | 106 | 0.010 |
Why?
| | Indazoles | 1 | 2000 | 66 | 0.010 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 4 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 128 | 0.010 |
Why?
| | Quality of Life | 1 | 2011 | 2695 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 6 | 0.010 |
Why?
| | Tetraethylammonium | 1 | 1999 | 17 | 0.010 |
Why?
| | Heart Rate, Fetal | 1 | 1999 | 21 | 0.010 |
Why?
| | 4-Aminopyridine | 1 | 1999 | 24 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1997 | 90 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1997 | 143 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 1997 | 76 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 171 | 0.010 |
Why?
| | Incidence | 1 | 2003 | 2646 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 326 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 172 | 0.010 |
Why?
| | Algorithms | 1 | 2000 | 1617 | 0.010 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|